title: Randomized controlled trial of three different doses of aerosol beclomethasone versus systemic dexamethasone to promote extubation in ventilated premature infants.
abstract: Our objective was to determine the safety and efficacy of aerosol beclomethasone vs. systemic dexamethasone for extubation in premature infants at high risk for chronic lung disease (CLD). Intubated preterm infants who were identified as being at high risk for moderate-severe CLD on day 14 of life were randomized to one of four groups. The control group received systemic dexamethasone and aerosol placebo, while the other three groups received either high (2.40-3.69 microg/kg/day delivered to lungs), medium (1.0-1.85 microg/kg/day), or low (0.48-0.74 microg/kg/day) dose aerosol beclomethasone and systemic placebo. Those receiving aerosol steroids who remained ventilator-dependent after 7 days were switched to standard 42-day tapering doses of systemic dexamethasone. The primary outcome was extubation within 1 week of starting steroids, using predefined criteria. Secondary variables included changes in lung function, rates of side effects, and tracheal aspirate white blood cell counts. Sixty-one infants with birth weights of 761 +/- 18 g (mean +/- SEM) and gestational ages of 25.7 +/- 0.2 weeks were randomized to one of the four groups. Seven of 15 infants in the control systemic dexamethasone group were successfully extubated compared with 3/16 in the high-dose beclomethasone group, 1/15 in the medium-dose group, and 2/15 in the low-dose group (P < 0.01). Only dexamethasone subjects demonstrated improvements in lung function over the study period. These infants also had significant increases in blood pressure and blood glucose levels, as well as a decline in their tracheal aspirate white blood cell count. In conclusion, aerosol beclomethasone at the very low doses used in this study did not facilitate extubation in intubated premature infants at high risk for moderate-severe CLD.
authors.affiliation: Department of Pediatrics, Medical College of Virginia at Virginia Commonwealth University, Richmond, Virginia 23298-0276, USA. hrozycki@hsc.vcu.edu
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Rozycki
authors.forename: Peter R
authors.initials: PR
authors.lastname: Byron
authors.forename: Greg R
authors.initials: GR
authors.lastname: Elliott
authors.forename: Timothy
authors.initials: T
authors.lastname: Carroll
authors.forename: Gary R
authors.initials: GR
authors.lastname: Gutcher
mesh_terms: D000280:Administration, Inhalation; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D020878:Device Removal / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D008171:Lung Diseases / Q000209:etiology* / Q000517:prevention & control*; D008297:Male; D017063:Outcome Assessment, Health Care; D012121:Respiration, Artificial / Q000009:adverse effects*; D012129:Respiratory Function Tests; D015300:Ventilator Weaning / Q000009:adverse effects*
chemical_list: D000893:Anti-Inflammatory Agents; D003907:Dexamethasone; D001507:Beclomethasone